The febrile neutropenic patient: newer options for empirical therapy.
Rubin
M
M
Infectious Disease Section, National Cancer Institute Bethesda, Maryland.
Walsh
T
T
Butler
K
K
Lee
J
J
Lecciones
J
J
Weinberger
M
M
Roilides
E
E
Gress
J
J
Marshall
D
D
Pizzo
P A
PA
D000380:Agranulocytosis / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D001398:Aztreonam / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D015780:Carbapenems / Q000009:adverse effects / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005334:Fever / Q000209:etiology*; D006801:Humans; D009503:Neutropenia / Q000150:complications*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; D015363:Quinolones; D001398:Aztreonam